GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and ...

Cohort A focused on patients with CLE or SLE with active lupus rash and evaluated organ-specific disease activity using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity ...

LDA states (Lupus Low Disease Activity State (LLDAS), disease control, clinical and complete remissions) were defined using SLE Disease Activity Index (SLEDAI)/Physician Global Assessment scores, ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025 ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory ...

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...

BOSTON, MA, USA I June 12, 2025 I EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, a leading science and ...

Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...

This unpredictable autoimmune disease presents unique challenges for people with it. This unpredictable autoimmune disease ...